Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-07-12 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
FWP
Regulatory Filings
2019-07-12 English
Genmab Commences Public Offering of American Depositary Shares (ADSs) in the United States
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement regarding the commencement of a public offering of American Depositary Shares (ADSs) and the filing of a preliminary prospectus with the SEC. While it discusses capital raising, it is primarily an announcement of a corporate action (the launch of an offering) rather than the prospectus itself. According to the 'Menu vs Meal' rule, this is a report publication announcement or a regulatory announcement regarding a specific corporate event. Given the specific nature of the announcement regarding share issuance and capital structure changes, it fits best under 'Share Issue/Capital Change' (SHA) as it details the issuance of new shares underlying the ADSs.
2019-07-09 English
Share Issue/Capital Change 2019
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement from Genmab A/S detailing the commencement of a public offering of American Depositary Shares (ADSs) in the United States. It explicitly mentions filing a preliminary prospectus with the SEC on Form F-1 and discusses the intention to use proceeds, the structure of the offering (Firm ADSs and Option ADSs), and the planned listing on Nasdaq. This activity—raising capital through the issuance of new securities—falls directly under the definition of a Capital/Financing Update.
2019-07-09 English
Share Issue/Capital Change 2019
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement from Genmab A/S detailing the commencement of a public offering of American Depositary Shares (ADSs) in the United States. It explicitly mentions filing a preliminary prospectus with the SEC on Form F-1 and discusses the intention to use proceeds, the structure of the offering (Firm ADSs and Option ADSs), and the planned listing on Nasdaq. This activity—raising capital through the issuance of new securities—falls directly under the definition of a Capital/Financing Update.
2019-07-09 English
Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newly Diagnosed Patients with Multiple Myeloma Treated with Daratumumab in Combination with Lenalidomide
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding positive topline results from a Phase II clinical trial (GRIFFIN study). It details the study's primary endpoints, safety profile, and implications for future research. It does not fit into financial reporting categories like 10-K or IR, nor is it a transcript or a governance report. As it is a standard regulatory announcement of clinical trial results, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for general corporate announcements that do not meet the criteria for more specific categories like M&A or dividend notices.
2019-07-08 English
Earnings Release 2019
Earnings Release Classification · 100% confidence The document is titled "Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study..." and is explicitly labeled as a "Company Announcement." It details the positive results of a clinical trial (GRIFFIN study) for a drug (daratumumab) and includes forward-looking statements and contact information typical of a press release regarding clinical data. This format strongly suggests an initial announcement of financial or operational results, which aligns best with the Earnings Release (ER) category, even though it pertains to clinical trial data rather than quarterly revenue/profit. Since the document is a comprehensive announcement of key results, it is not a mere Report Publication Announcement (RPA). Given the options, ER is the closest fit for a major operational/data announcement press release. Q3 2019
2019-07-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.